🏛️ Verified NIH Record • Updated 2026-08-27

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) (NCT07519772)

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (15 items).

Location: Colorado Blood Cancer Institute ( Site 7000) — Denver, Colorado

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: The main exclusion criteria include but are not limited to the following:
  • Has received a solid organ transplant.
  • Had or has clinically relevant central nervous system (CNS) diseases.
  • Has a history of serious cardiovascular or cerebrovascular diseases.
  • Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.
  • Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has received a live or live-attenuated vaccine within 30 days of randomization.
  • Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.
  • Has a known additional malignancy that is progressing or required active treatment within the past 2 years.
  • Has known active CNS lymphoma or involvement.
  • Has active autoimmune disease that required systemic treatment in the past 2 years.
  • Has active infection requiring systemic therapy.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (35 Sites)

Showing the first 25 of 35 sites.

  • Colorado Blood Cancer Institute ( Site 7000) — Denver, Colorado
  • SCRI Oncology Partners ( Site 0100) — Nashville, Tennessee
  • Instituto Alexander Fleming ( Site 1404) — Ciudad Autonoma de Buenos Aires, Buenos Aires
  • Sanatorio Nuestra Senora del Rosario ( Site 1403) — Rosario, Santa Fe Province
  • Townsville University Hospital ( Site 0204) — Townsville, Queensland
  • Box Hill Hospital ( Site 0202) — Box Hill, Victoria
  • Princess Margaret Cancer Centre ( Site 0301) — Toronto, Ontario
  • Beijing Cancer hospital ( Site 1701) — Beijing, Beijing Municipality
  • Sun Yat-Sen University Cancer Center ( Site 1712) — Guangzhou, Guangdong
  • Fudan University Shanghai Cancer Center ( Site 1711) — Shanghai, Shanghai Municipality
  • Carmel Hospital ( Site 0602) — Haifa,
  • Shaare Zedek Medical Center ( Site 0603) — Jerusalem,
  • Haddasah Medical Center ( Site 0600) — Jerusalem,
  • Sheba Medical Center ( Site 0601) — Ramat Gan,
  • Sourasky Medical Center. ( Site 0604) — Tel Aviv,
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Ematologia Oncologica ( Site 0700) — Campania, Napoli
  • INOC - Istituto Nazionale Oncologico Candiolo ( Site 0701) — Candiolo, Piedmont
  • Istituto Europeo di Oncologia IRCCS ( Site 0702) — Milan,
  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0705) — Roma,
  • Pratia MCM Krakow ( Site 0903) — Krakow, Lesser Poland Voivodeship
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900) — Warsaw, Masovian Voivodeship
  • Pratia Onkologia Katowice ( Site 0902) — Katowice, Silesian Voivodeship
  • The Catholic University of Korea, Yeouido St. Mary's Hospital ( Site 0801) — Seoul,
  • Institut Català d'Oncologia (ICO) - Badalona ( Site 1103) — Badalona, Barcelona
  • Hospital Virgen de la Victoria ( Site 1104) — Málaga, Malaga

📞 Contact the Study Coordinator

Phone: (888) 577-8839

Email: Trialsites@msd.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma, Non-Hodgkin

Explore by condition: All Lymphoma, Non-Hodgkin clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗